Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06639503 · ClinicalTrials.gov registry record · Phase 1
Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau
A Phase 1 study of Tibial Plateau Fractures, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06639503 is a Phase 1 study of Tibial Plateau Fractures that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06639503, a Phase 1 study of Tibial Plateau Fractures, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.
Conditions Studied
Interventions
- DRUG Bupivacain
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2026-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06639503
The ClinicalTrials.gov registry entry for NCT06639503 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tibial Plateau Fractures appearing as the primary indexed condition, and to 1 intervention - of which Bupivacain is the first listed.
NCT06639503 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06639503 about?
NCT06639503 is a clinical study titled "Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau". The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if prov...
What is the current status of trial NCT06639503?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2024-11-01. Estimated completion is 2026-10-14.
What conditions does trial NCT06639503 study?
This clinical trial studies the following conditions: Tibial Plateau Fractures.
What interventions are being tested in trial NCT06639503?
The interventions under investigation include: Bupivacain (DRUG).
Who is sponsoring clinical trial NCT06639503?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06639503 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tibial Plateau Fractures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.